Cargando…
TIGIT in cancer immunotherapy
Tumors evade immune-mediated recognition through multiple mechanisms of immune escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and upregulate various checkpoint inhibitory receptors (IRs) that limit T cells’ survival and function. During the last decade, immunothera...
Autores principales: | Chauvin, Joe-Marc, Zarour, Hassane M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477968/ https://www.ncbi.nlm.nih.gov/pubmed/32900861 http://dx.doi.org/10.1136/jitc-2020-000957 |
Ejemplares similares
-
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
por: Davar, Diwakar, et al.
Publicado: (2022) -
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021) -
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023) -
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022) -
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)